Loading
Latest filing published 26 Jun 2023 for DiaMedica Therapeutics Inc., €36k. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Scott Kellen is a declared insider of DiaMedica Therapeutics Inc. (finance chief), with filings sourced from SEC (Form 4). We count 2 filings; the first trade dates from 16 August 2021 and the latest from 23 June 2023.
The open-market record is one-sided, with 2 purchases worth €62k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2023: 1 purchase and no sales on the market.
The latest filing, published on 26 June 2023, reports an open-market purchase of €36k in DiaMedica Therapeutics Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations